secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-117257
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia Q3 net sales $6.1M (+5% YoY); proprietary products up 26%; narrows net loss; to file 510(k) for CanGarooRM in Q4
--------------------------------------------------------------------------------

- Net loss from continuing ops $8.5M ($0.50/sh), improving from $11.0M ($0.81/sh) YoY.
- Proprietary product sales (SimpliDerm +44%, CanGaroo +11% YoY) drove 26% overall proprietary growth; total net sales $6.1M.
- Completed Orthobiologics divestiture for initial $15M, plus private placement netting $10.5M; cash balance $14.5M at Sept 30.
- Anticipates FDA 510(k) filing for CanGarooRM by year-end 2023, targeting $600M drug-eluting CIED envelope market.
- Operating expenses down 14% YoY to $10.2M; gross margin declined to 46.4% from 50.2% due to distributor pricing shift.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/0001104659-23-117257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/tm2330559d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer